June 5, 2025 | Berlin, Germany
Eckert & Ziegler (ISIN DE0005659700, TecDAX) congratulates Telix Pharmaceuticals Limited (Telix) on the approval of its prostate cancer PET imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection) in Germany, where Eckert & Ziegler Radiopharma GmbH is the official distributor.
With Illuccix®, Eckert & Ziegler will now significantly extend its portfolio in nuclear medicine with a widely clinically validated PSMA tracer, which perfectly complements its proprietary 68Ge/68Ga Radionuclide Generator, GalliaPharm®. GalliaPharm® is widely used as a high-quality GMP grade generator for Gallium-68 in Germany and globally, supporting the production of radiopharmaceuticals for positron emission tomography (PET) imaging, particularly in oncology.
“Our collaboration with Telix on Illuccix® leverages our established distribution network and market expertise to ensure broad access to this important PSMA-PET imaging agent in Germany. This partnership reinforces our commitment to delivering advanced diagnostic solutions for prostate cancer care”, commented Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE.
Raphaël Ortiz, Chief Executive Officer, Telix International added: “We are pleased that Illuccix®, which has played a key role in the advancement of PSMA-PET imaging internationally, has been approved in Germany. We are looking forward to working with Eckert & Ziegler to make our gallium-based PSMA-PET imaging agent accessible here.”
About Eckert & Ziegler
Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.
Contact
Eckert & Ziegler SE
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Jan Schöpflin, Marketing / Karolin Riehle, Investor Relations
jan.schoepflin@ezag.com / karolin.riehle@ezag.com
Tel.: +49 (0) 30 / 94 10 84-138; www.ezag.com
